Creating a movement from the inside out – to break the stigma of mental health conditions and empower employees to be champions of brain health Learn more at www.MentalHealthActionDay.org CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 20, 2021-- Sage Therapeutics (Nasdaq:SAGE), a biopharmaceutical company

Debut webcast to provide deep dive on SAGE-718, the company’s lead neuropsychiatry product candidate being studied for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s, Parkinson’s, and Alzheimer’s diseases Webcast scheduled for 8:30 a.m.

Company on-track to initiate placebo-controlled Phase 2 trial with SAGE-718 in Huntington’s disease in late 2021, as the target for the first indication for SAGE-718, following encouraging signals in Phase 1 data PARADIGM Study with SAGE-718 showed improved performance from baseline on multiple

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 28, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast

Statistically significant reduction in tremor score compared to placebo at Day 29 in adults with essential tremor SAGE-324 demonstrated a 36% reduction in upper limb tremor amplitude from baseline at Day 29 in the total studied population; in a more severe population (baseline TETRAS Upper Limb

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 24, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will

In the now completed 30 mg zuranolone cohort, approximately 70% of participants with positive response to an initial 2-week treatment required at most one additional zuranolone treatment during the 12-month study After the initial 2-week zuranolone treatment, more than 70% of patients who received

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2021-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that Mike Cloonan , Sage’s Chief Operating

Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one year Progressed WATERFALL Study – now closed to enrollment – investigating zuranolone for as needed